Bone Biologics

Historical price data

Bone Biologics is a clinical-stage biotech focused on developing novel, targeted biologic therapeutics for bone regeneration, with an initial focus on spinal fusion. Its core asset is the recombinant human NELL-1 protein, engineered to be a potent and selective osteoinductive agent that may offer safety advantages over historical BMPs. The company's strategy is to advance its lead NELL-1/DBM combination product through clinical trials to address a significant unmet need in orthopedic surgery. As a micro-cap public entity, it operates with a lean structure, directing resources toward key clinical milestones.

Proprietary recombinant human NELL-1 protein, a potent and bone-specific osteoinductive factor designed to stimulate targeted bone growth with a potentially improved safety profile compared to historical BMPs.

Competes against the gold standard autograft, widely used allografts, commercial BMPs (e.g., Medtronic's INFUSE®), synthetic grafts, and cell-based therapies. Its key differentiation is the claimed bone-specificity and improved safety profile of its NELL-1 protein compared to first-generation BMPs.